Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects (Q38004964)

26 August 2017

0 references

Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects (English)

1 reference

26 August 2017

0 references

0 references

0 references

1 reference

2

1 reference

26 August 2017

George Anderson

1

1 reference

26 August 2017

25 April 2012

1 reference

26 August 2017

Metabolic Brain Disease

1 reference

26 August 2017

27

1 reference

26 August 2017

2

1 reference

26 August 2017

113-119

1 reference

https://scigraph.springernature.com/pub.10.1007/s11011-012-9307-9

26 August 2017

0 references

cites work

Schizophrenia patients with predominantly positive symptoms have more disturbed sleep-wake cycles measured by actigraphy.

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Alzheimer's and seizures: interleukin-18, indoleamine 2,3-dioxygenase and quinolinic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Prematurity is related to high placental cortisol in preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Vitamin D and immune function: understanding common pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Oxidative stress in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Prenatal infection and schizophrenia: a review of epidemiologic and translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Caloric restriction, SIRT1 and longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Back to the future: a new look at 'old' vitamin D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

The unchanging mortality gap for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Antiinflammatory activity of melatonin in central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Strategies to close the "mortality gap".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Human placental trophoblasts synthesize melatonin and express its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

The role of melatonin in the immuno-neuro-psychology of mental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin as a potential therapeutic agent in psychiatric illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Sleep induced by the administration of melatonin (5-methoxy-N-acetyltryptamine) to the hypothalamus in unrestrained cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Conception season and cerebral asymmetries among American baseball players: implications for the seasonal birth effect in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Vitamin D and innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Seasonal variation in human brain serotonin transporter binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin prevents glucocorticoid inhibition of cell proliferation and toxicity in hippocampal cells by reducing glucocorticoid receptor nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin promotes neurogenesis in dentate gyrus in the pinealectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin improves memory acquisition under stress independent of stress hormone release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

The relationship of pineal calcification to cortical atrophy in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Weight gain profiles of new anti-psychotics: public health consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Low vitamin D may explain the link between preeclampsia and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-012-9307-9

Sleep and circadian rhythm disruption in schizophrenia

21 January 2018

1 reference

12 December 2020

Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls

1 reference

12 December 2020

Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics

1 reference

12 December 2020

Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients.

1 reference

12 December 2020

Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep

1 reference

12 December 2020

Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells

1 reference

12 December 2020

A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.

1 reference

12 December 2020

Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.

1 reference

12 December 2020

Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesian Chinese Han patients with schizophrenia

1 reference

12 December 2020

Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.

1 reference

12 December 2020

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.

1 reference

12 December 2020

Vitamin D in schizophrenia, major depression and alcoholism

1 reference

12 December 2020

Seasonal variation of nutrient intake in pregnancy: effects on infant measures and possible influence on diseases related to season of birth

1 reference

12 December 2020

Is melatonin treatment effective for tardive dyskinesia?

1 reference

12 December 2020

Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia

1 reference

12 December 2020

Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study

1 reference

12 December 2020

Vitamin D, innate immunity and outcomes in community acquired pneumonia

1 reference

12 December 2020

10.1007/S11011-012-9307-9

Identifiers

DOI

1 reference

PubMed ID

22527998

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22527998